Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA6 | P23280 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
| ▸ | TTR | P02766 | 5/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479478 | 1.00 | RXRA (0.55) | RXRACA12CA7CA9CA14 | |
| SCHEMBL6473217 | 0.92 | RXRA (0.50) | RXRACA12CA7CA9CA14 | |
| SCHEMBL6479699 | 0.92 | RXRA (0.50) | RXRACA12CA7CA9CA14 | |
| SCHEMBL6479229 | 0.92 | RXRA (0.50) | RXRACA12CA7CA9CA14 | |
| SCHEMBL6479230 | 0.92 | RXRA (0.50) | RXRACA12CA7CA9CA14 | |
| SCHEMBL6479697 | 0.92 | RXRA (0.50) | RXRACA12CA7CA9CA14 | |
| SCHEMBL6473219 | 0.92 | RXRA (0.50) | RXRACA12CA7CA9CA14 | |
| SCHEMBL6472256 | 0.91 | FDPS (0.51) | CA12CA7CA9CA14CA4 | |
| SCHEMBL6472257 | 0.91 | FDPS (0.51) | CA12CA7CA9CA14CA4 | |
| SCHEMBL6472798 | 0.90 | RXRA (0.48) | RXRACA12CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | RXRA 174/4885CA12 4307/4885CA7 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.